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OBJECTIVES This study was designed to evaluate the beneficial effect of beta-blockers on circulating
cytokine levels in patients with dilated cardiomyopathy (DCM).
BACKGROUND Elevated circulating levels of inflammatory cytokines have been reported in patients with
DCM. However, alterations of the levels of inflammatory and anti-inflammatory cytokines in
association with beta-blocker therapy are unknown.
METHODS We studied 32 patients with idiopathic DCM who had been treated with digitalis, diuretics
and angiotensin-converting enzyme inhibitors. In addition to this combination therapy,
beta-blockers were started in all patients. Serum levels of interleukin (IL)-10, tumor necrosis
factor-alpha (TNF-alpha) and soluble TNF receptors (sTNF-R1 and R2) were measured at
baseline and 12 weeks after the initiation of beta-blocker therapy. We also measured plasma
levels of neurohumoral factors, as well as left ventricular (LV) size and function. Ten
age-matched subjects with no cardiac disease served as the control group.
RESULTS Baseline levels of IL-10, TNF-alpha and sTNF-R2 were significantly higher in patients with
DCM than in control subjects (p , 0.05). There was a significant positive correlation
between IL-10 and TNF-alpha levels (r 5 0.545, p 5 0.029). The TNF-alpha/IL-10 ratio
correlated well with plasma epinephrine levels (r 5 0.677, p 5 0.025), and the level of
sTNF-R2 was closely related to LV size. Serum levels of IL-10, TNF-alpha and sTNF-R2
were significantly decreased during beta-blocker therapy (p , 0.005).
CONCLUSIONS Our findings indicate that beta-blockers have an important immunoregulatory role in
modifying the dysregulated cytokine network in DCM. This effect of beta-blockers may be
partly responsible for the efficacy of therapeutic drugs for heart failure. (J Am Coll Cardiol
2001;37:412–7) © 2001 by the American College of Cardiology
Beta-adrenergic blocking agents have been considered to be
useful for patients with congestive heart failure (CHF).
Large clinical trials have indicated their beneficial effects on
morbidity and mortality in such patients (1–4). Very re-
cently, we demonstrated the attenuating effect of beta-
blockers on plasma natriuretic peptide levels in patients with
idiopathic dilated cardiomyopathy (DCM) who were
treated with a combination of diuretics, digitalis and
angiotensin-converting enzyme (ACE) inhibitors (5).
However, the exact mechanisms of the beneficial effects of
beta-blockers have not been elucidated.
Previous studies have shown the increased circulating
levels of various inflammatory cytokines in patients with
CHF (6–8). It is well known that the overexpression of
these inflammatory cytokines can produce left ventricular
(LV) dysfunction, pulmonary edema and cardiomyopathy in
humans (9). In particular, tumor necrosis factor-alpha
(TNF-alpha) and interleukin (IL)-6 are important in asso-
ciation with the progression of CHF. Tumor necrosis
factor-alpha is synthesized by activated macrophages, endo-
thelial cells and the myocardium; it also induces cachexia
and apoptosis in myocardial cells and produces negative
inotropic effects on cardiac tissue (10–12). Two TNF
receptors of 55 and 75 kD have been identified on the
surface of cell lines and are thought to mediate and regulate
most of the effects of TNF-alpha (13,14). Soluble forms of
both receptors (sTNF-R1 and R2), the extracellular domain
fragments shed from cell surfaces, are supposed to regulate
the TNF-alpha bioactivity by inhibiting the binding of
TNF trimmers to the membrane receptors (15). Therefore,
circulating levels of sTNF receptors are closely related to the
activities of TNF-alpha. Moreover, the effects of TNF-
alpha are modulated by anti-inflammatory cytokines.
Interleukin-10, a cytokine with anti-inflammatory activities,
is known to suppress the synthesis of TNF-alpha and to
enhance the release of sTNF receptors (16). A recent report
has shown that circulating levels of IL-10 are markedly
increased in patients with CHF (17). In view of these
findings, a dysregulated cytokine network is involved in the
development and progression of CHF. In addition, the
effects of various cardiovascular treatments on the levels of
these cytokines and cytokine receptors are largely unknown.
Accordingly, this study was designed to evaluate the
beneficial effect of beta-blockers on circulating cytokine
levels in patients with DCM and to clarify the alterations of
the levels of inflammatory and anti-inflammatory cytokines
and cytokine receptors in relation to beta-blocker therapy.
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METHODS
Subjects. We studied 32 consecutive patients with idio-
pathic DCM (11 women and 21 men) between June 1996
and May 1999. They were in New York Heart Association
functional class II or III and had been treated with digitalis,
diuretics and ACE inhibitors for at least six months. They
ranged in age from 26 to 74 years (mean 61). Patients who
had clinical or laboratory evidence of neoplasms or autoim-
mune disease or liver or renal dysfunction were excluded
from the study. Ten age-matched subjects who had no
evidence of organic cardiac disease and no cardiac dysfunc-
tion were retrospectively selected as the control group. All
subjects participated in this study after giving their informed
consent, and the protocol was approved by the Human
Investigations Committee of our institution.
Study protocol. In all patients, beta-blockers were admin-
istered orally, in addition to the combination therapy after
their hospital admission (29 patients received metoprolol
and 3 received bisoprolol). The initial dosages of metoprolol
and bisoprolol were 2.5 or 5.0 mg and 1.25 or 2.5 mg/day,
respectively. The doses were gradually increased up to the
maximum levels, which were determined by the end point of
either a decrease in systolic blood pressure ,90 mm Hg or
a decrease in heart rate at rest ,50 beats/min during eight
weeks. The mean final doses of metoprolol and bisoprolol
were 37.3 mg (range 15 to 80) and 8.3 mg (range 5.0 to
12.5), respectively. After determining the final doses, the
patients were followed for an additional four weeks.
Blood sampling and immunoassays. After bed rest for at
least 30 min, peripheral venous blood samples were col-
lected into chilled tubes and immediately centrifuged at
4°C, and the serum samples were stored at 280°C until
assay. Blood samples from patients for the measurement of
levels of IL-10, TNF-alpha and sTNF receptors were
collected before and 12 weeks after the initiation of beta-
blocker therapy. At the same time, plasma levels of epineph-
rine, norepinephrine, atrial natriuretic peptide (ANP) and
brain natriuretic peptide (BNP) were also measured in
patients, as previously reported (18,19).
Serum levels of IL-10, TNF-alpha and sTNF receptors
(sTNF-R1 and R2) were measured by enzyme-linked im-
munosorbent assays with commercial kits (Immunotech
Co., Marseille, France), as previously reported (20,21). The
average interassay and intra-assay coefficients of variation
were ,10% for all assays.
Echocardiographic study. Echocardiographic studies were
performed using an SSD-870 echocardiograph with a 3.5-
MHz transducer (Aloka Inc., Tokyo, Japan), according to
the recommendations of the American Society of Echocar-
diography (22). In each patient, a standard parasternal
long-axis view was recorded at the basal position, and the
LV end-diastolic dimension (EDD) and end-systolic di-
mension (ESD) were determined using M-mode echocar-
diography. Percent LV fractional shortening was calculated
as LV systolic function: ([EDD 2 ESD]/EDD 3 100).
Statistical analysis. All data are expressed as the mean
value 6 SD. Differences between patients and control
subjects were compared by using the Mann-Whitney U
rank-sum test for unpaired data. Clinical variables and
serum levels of cytokines in patients were compared before
and during beta-blocker therapy using the Wilcoxon paired
sign-rank test. Correlation coefficients for relations between
serum levels of cytokines and cytokine receptors and be-
tween their levels and clinical variables were tested by using
the Spearman rank test. A p value ,0.05 was considered
statistically significant.
RESULTS
Baseline levels of IL-10, TNF-alpha and sTNF receptors.
Figure 1 shows the serum levels of IL-10, TNF-alpha,
sTNF-R1 and sTNF-R2 in patients with DCM at baseline
and in control subjects. Serum levels of IL-10 and TNF-
alpha were significantly higher in patients with DCM than
in control subjects (Fig. 1, A and B). Serum sTNF-R2 levels
were also higher in patients with DCM than in control
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
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Figure 1. Graphs showing the serum levels of IL-10 (A), TNF-alpha (B),
sTNF-R1 (C) and sTNF-R2 (D) in 10 age-matched control subjects and
in 32 patients with DCM at baseline. *p , 0.05. **p , 0.005 vs. control
subjects.
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subjects (Fig. 1D). However, there was no significant
difference in the serum levels of sTNF-R1 between the two
groups (Fig. 1C).
Relations among IL-10 and TNF-alpha and sTNF re-
ceptors in patients with DCM. In patients with DCM,
there was a significant correlation between serum levels of
IL-10 and TNF-alpha at baseline (r 5 0.545, p 5 0.029)
(Fig. 2). However, there were no significant correlations
between serum levels of IL-10 and sTNF-R1 and sTNF-R2
levels. In addition, there were no significant correlations
between serum levels of TNF-alpha and sTNF-R1 and
sTNF-R2 levels.
Relations between IL-10, TNF-alpha or sTNF receptors
and clinical variables in patients with DCM. In patients
with DCM, there were no significant correlations between
serum levels of IL-10 and TNF-alpha and neurohumoral
factors, LV size and systolic function at baseline. In addi-
tion, both sTNF-R1 and sTNF-R2 levels did not signifi-
cantly correlate with levels of neurohumoral factors. In
contrast, there was a significant correlation between the
serum level of sTNF-R2 and EDD (r 5 0.604, p 5 0.012)
(Fig. 3A), although no correlation was found between
sTNF-R1 and EDD. Moreover, the ratio of TNF-alpha/
IL-10 significantly correlated with plasma epinephrine lev-
els (r 5 0.677, p 5 0.025) (Fig. 3B).
Effects of beta-blockers on clinical variables. Table 1
shows the effects of beta-blockers on hemodynamic vari-
ables, LV function and neurohumoral factors in patients
with DCM. After treatment with beta-blockers, heart rates
were significantly decreased and New York Heart Associa-
tion functional classes were significantly improved, although
systolic blood pressures remained unchanged. In addition,
LV size and systolic function were significantly improved,
and plasma levels of epinephrine, norepinephrine, ANP and
BNP were significantly reduced during beta-blocker therapy.
Effects of beta-blockers on levels of cytokines and cyto-
kine receptors. Figure 4 demonstrates the effects of beta-
blockers on serum levels of IL-10, TNF-alpha, sTNF-R1
and sTNF-R2 in patients with DCM. After treatment with
beta-blockers, increased levels of both IL-10 and TNF-
alpha were significantly reduced (Fig. 4, A and B). Serum
levels of sTNF-R2 also decreased significantly, although
levels of sTNF-R1 remained unchanged during beta-
blocker therapy (Fig. 4, C and D).
DISCUSSION
Increased circulating levels of inflammatory cytokines have
been shown in patients with CHF, but most studies have
focused on only a few inflammatory cytokines (23,24). Most
of the effects of these inflammatory cytokines are regulated
by anti-inflammatory cytokines and cytokine receptors. In
addition, little is known about the effects of various cardio-
vascular treatment regimens on the levels of these cytokines
and cytokine receptors. In the present study, we demon-
strated the major alterations not only in the levels of
inflammatory cytokines, but also in the levels of anti-
inflammatory cytokines and cytokine receptors in patients
with DCM. Our findings clearly indicate that beta-blockers
markedly reduce the increased circulating levels of TNF-
alpha, and that the reduction of TNF-alpha levels is closely
related to the alterations in the levels of IL-10 and sTNF-
R2.
Effects of beta-blockers on TNF-alpha levels. Previous
studies have indicated the beneficial effects of various
cardiovascular treatments on levels of inflammatory cyto-
kines in patients with CHF (24–27). Several reports have
shown a significant reduction in circulating IL-6 levels due
to ACE inhibitor therapy in CHF (26,27). In particular,
Gullestad et al. (27) have indicated that high dose enalapril
therapy markedly decreases IL-6 activity in patients with
CHF. However, a significant reduction of circulating TNF-
alpha levels in patients treated with ACE inhibitors was not
observed in these studies. Mohler et al. (25) have shown that
the calcium antagonist, amlodipine, lowers plasma IL-6
levels in patients with CHF, but they found no effect of
amlodipine on plasma levels of TNF-alpha. These results
indicate that treatment with ACE inhibitors and some type
of calcium antagonist cannot affect TNF-alpha levels of the
circulation in patients with CHF. Therefore, we think that
TNF-alpha is an another important therapeutic target in
CHF.
In this study, we elucidated, for the first time, to our
knowledge, that beta-blockers markedly lower the increased
Figure 3. Scatterplots showing correlations (A) between sTNF-R2 and left
ventricular end-diastolic dimension (LVEDD) and (B) between plasma
epinephrine levels and the TNF-alpha/IL-10 ratio in 32 patients with
DCM.
Figure 2. Scatterplots showing a correlation between IL-10 and TNF-
alpha in 32 patients with DCM.
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circulating level of TNF-alpha in patients with DCM. This
finding suggests that the beneficial effect of beta-blockers in
CHF may be partly due to a suppression of TNF-alpha
activities in the circulation. Very recently, Prabhu et al. (28)
reported that the beta-blocker, metoprolol, selectively de-
creased myocardial expression of TNF-alpha and IL-1-beta,
but not IL-6, in rats with LV dysfunction after myocardial
infarction. In addition, it was reported that treatment with
beta-blockers in patients with CHF did not change the
plasma IL-6 levels (24). In view of these reported data and
our results, there seems to be at least two major cytokine
networks related to the condition of CHF. One is a network
mainly associated with IL-6, which is influenced by ACE
inhibitors and some type of calcium antagonist. The other is
a network mainly regulated by TNF-alpha, which is influ-
enced by beta-blockers. Very recently, we reported that
beta-blocker therapy could reduce the plasma levels of ANP
and BNP and improve the LV remodeling in patients with
heart failure treated with ACE inhibitors (5). This finding
indicates that the mechanism for the beneficial effect of
beta-blockers is different from that of ACE inhibitors.
Therefore, combination therapy with beta-blockers and
ACE inhibitors in patients with DCM may perfectly
modify the dysregulated networks associated with two major
inflammatory cytokines.
Alteration of sTNF receptor levels. Most of the effects of
TNF-alpha are mediated through two TNF receptors and
anti-inflammatory cytokines. The two soluble TNF recep-
tors circulate in normal serum, and high levels of these
receptors are present in patients with CHF (8). In particu-
lar, it is known that the levels of sTNF-R2 are strongly
correlated with clinical variables, such as ejection fraction
and cardiac output, and are closely related to a poor
prognosis in patients with CHF (29). In our study, we also
demonstrated increased circulating levels of sTNF-R2 in
patients with DCM, although no elevation of sTNF-R1
was found. The levels of sTNF-R2 were markedly de-
creased, in accordance with the reduction of TNF-alpha
levels, due to beta-blocker therapy. These findings suggest
that sTNF-R2 is a very important factor in modulating
TNF-alpha activities in patients with DCM. In addition, a
recent study has shown that etanercept, a sTNF-R2 fusion
protein that binds to TNF-alpha, leads to improvement in
the functional status of patients with advanced CHF (30).
Our findings show that the increased levels of sTNF-R2
were closely related to LV size in DCM. In contrast, the
increase of circulating sTNF-R2 was not associated with
activation of neurohumoral factors. Therefore, the LV
functional status of patients with DCM may be partly
determined by levels of sTNF-R2.
Relations between TNF-alpha and IL-10 in DCM. In
addition to an increased circulating level of sTNF-R2, our
patients also had alterations in IL-10 levels. Interleukin-10
downregulates the production of inflammatory cytokines in
a variety of cell types and enhances the release of sTNF
receptors; thus, it is known that IL-10 has potential
Table 1. Effects of Beta-Blocker Therapy on Hemodynamic Variables, Left Ventricular
Functions and Neurohumoral Factors in Patients With Dilated Cardiomyopathy
Variables Baseline Week 12 p Value
Heart rate (beats/min) 71.7 6 12.4 65.5 6 8.20 0.0098
Systolic blood pressure (mm Hg) 116.8 6 13.0 114.3 6 14.4 0.1831
New York Heart Association functional class 2.15 6 0.65 1.85 6 0.61 0.0285
Echocardiographic values
LVEDD (mm) 69.6 6 11.6 64.0 6 7.51 0.0014
LVESD (mm) 59.2 6 12.7 50.4 6 9.79 0.0010
Fractional shortening (%) 15.5 6 5.91 21.8 6 7.02 0.0026
Neurohumoral factors
Epinephrine (pg/ml) 310.2 6 52.6 141.5 6 22.4 0.0033
Norepinephrine (pg/ml) 341.1 6 33.9 218.4 6 34.0 0.0021
ANP (pg/ml) 83.4 6 27.4 60.2 6 26.5 0.0031
BNP (pg/ml) 253.5 6 112.2 184.8 6 114.0 0.0008
Data are presented as the mean value 6 SD.
ANP 5 atrial natriuretic peptide; BNP 5 brain natriuretic peptide; LVEDD 5 left ventricular end-diastolic dimension;
LVESD 5 left ventricular end-systolic dimension.
Figure 4. Comparisons of serum levels of IL-10 (A), TNF-alpha (B),
sTNF-R1 (C) and sTNF-R2 (D) at baseline and 12 weeks after the
initiation of beta-blocker therapy in 32 patients with DCM. *p , 0.005.
**p , 0.001 vs. control subjects.
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beneficial effects in terms of its cardioprotective properties
in CHF (31,32). However, to date, the mechanism involved
in a high level of IL-10 production in CHF remains
undefined. Our findings demonstrate that circulating levels
of IL-10 increased in relation to elevated TNF-alpha levels
in patients with DCM, and may support the concept that
the increase of IL-10 levels enhances the release of sTNF-
R2. Moreover, increased levels of IL-10 were markedly
decreased, in accordance with the reduction of TNF-alpha
levels, due to beta-blocker therapy. Therefore, IL-10 may be
a potential therapeutic agent, as an immunoregulatory
factor, in CHF.
One of the major findings in our study is that the
TNF-alpha/IL-10 ratio was strongly correlated with plasma
epinephrine levels in patients with DCM. Indeed, several
reports have clarified the relation between cytokine activities
and sympathetic activation. Yamaoka et al. (17) have re-
ported that the levels of catecholamines are associated with
IL-10 production in patients with CHF. In particular,
epinephrine is related to IL-10 production in lipopolysac-
charide stimulation through an increase in intracellular
cyclic adenosine monophosphate levels (33). In addition, a
very recent report has shown that activation of the adren-
ergic nervous system contributes to increased myocardial
expression of TNF-alpha in rats with heart failure (28).
Thus, we suggest that beta-blockade may regulate the
balance between TNF-alpha and IL-10 levels in patients
with DCM. Accordingly, beta-blockers may have an im-
portant immunoregulatory role in establishing the optimal
level of IL-10 for suppressing TNF-alpha production in
DCM.
Study limitations. One limitation of our study is that the
cellular source of circulating IL-10, TNF-alpha or sTNF
receptors is not known yet. To determine whether these
cytokines and sTNF receptors are released from the heart,
we must compare their levels in the coronary sinus with
those levels in other organs. We excluded from this study
patients who had clinical or laboratory evidence of malig-
nancy or inflammatory disease or liver or renal dysfunction.
In addition, circulating levels of IL-10, TNF-alpha and
sTNF-R2 were markedly decreased, in accordance with the
improvement of LV size and function during beta-blocker
therapy. Therefore, it is likely that their source is associated
with secretion from the heart. To confirm this, however,
further studies must be performed. Another limitation of
this study is the lack of a placebo group. Although circu-
lating TNF-alpha levels were found to reduce by beta-
blocker therapy, we cannot exclude the alterations of TNF-
alpha activities that might exist without beta-blockade.
However, the patients in our study showed increased circu-
lating levels of TNF-alpha, despite combination therapy
with digitalis, diuretics and ACE inhibitors. Thus, we think
that cardiovascular agents, except for beta-blockers, can not
affect TNF-alpha activities in the circulation of patients
with CHF.
Conclusions. We have clarified that beta-blockers can
lower the circulating level of TNF-alpha in patients with
DCM, and that the reduction of TNF-alpha levels was
closely related to the alterations of circulating levels of
IL-10 and sTNF-R2. In view of these findings, the bene-
ficial effect of beta-blockade may involve the attenuation of
TNF-alpha activities and the enhancement of the release of
sTNF-R2 by increasing the levels of anti-inflammatory
cytokines in CHF. Therefore, beta-blockers may have an
important immunoregulatory effect to modify the dysregu-
lated cytokine network in DCM.
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